Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus- infected patients: A randomized, controlled, multicenter study

Andrew Carr, Scan Emery, Andrew Lloyd, Jennifer Hoy, Roger Garsia, Martyn French, Graeme Stewart, Gwendolyn Fyfe, David A. Cooper

Research output: Contribution to journalArticleResearchpeer-review

81 Citations (Scopus)

Abstract

The safety and activity of outpatient-based continuous intravenous interleukin-2 (CIV IL-2) or a slow-release, polyethylene glycol (PEG)- modified IL-2 were studied in human immunodeficiency virus (HIV)-infected persons with CD4 cell counts between 200 and 500/mm3. One hundred fifteen patients were randomized to antiretroviral therapy plus cyclical CIV IL-2 (n = 27), subcutaneous PEG IL-2 (n = 58), or no IL-2 (n = 30). Toxicity withdrawal rates were low (4% for CIV IL-2 and 7% for PEG IL-2). There were median CD4 cell count increases of 359 and 44 cells/mm3 and a decline of 46 cells/mm3 in the 3 groups, respectively, over 1 year (P < .0001 for each intergroup comparison). CD4 cell count increases were greatest in those with lower HIV RNA load. Delayed-type hypersensitivity scores increased and HLA- DR expression on CD8 cells decreased significantly with IL-2 therapy. HIV RNA levels were unaffected. IL-2 therapy may expand the existing immune repertoire but not immediately reconstitute lost immune function.

Original languageEnglish
Pages (from-to)992-999
Number of pages8
JournalJournal of Infectious Diseases
Volume178
Issue number4
DOIs
Publication statusPublished - 1 Jan 1998

Cite this